Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Accumulated Depreciation: 2015-2024

Historic Accumulated Depreciation for Seres Therapeutics (MCRB) over the last 10 years, with Dec 2024 value amounting to $53.2 million.

  • Seres Therapeutics' Accumulated Depreciation rose 8.06% to $56.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $56.4 million, marking a year-over-year increase of 8.06%. This contributed to the annual value of $53.2 million for FY2024, which is 8.39% up from last year.
  • Per Seres Therapeutics' latest filing, its Accumulated Depreciation stood at $53.2 million for FY2024, which was up 8.39% from $49.1 million recorded in FY2023.
  • Over the past 5 years, Seres Therapeutics' Accumulated Depreciation peaked at $53.2 million during FY2024, and registered a low of $34.3 million during FY2020.
  • Moreover, its 3-year median value for Accumulated Depreciation was $49.1 million (2023), whereas its average is $49.1 million.
  • Data for Seres Therapeutics' Accumulated Depreciation shows a peak YoY increased of 23.71% (in 2020) over the last 5 years.
  • Yearly analysis of 5 years shows Seres Therapeutics' Accumulated Depreciation stood at $34.3 million in 2020, then climbed by 17.33% to $40.3 million in 2021, then grew by 11.85% to $45.0 million in 2022, then climbed by 8.97% to $49.1 million in 2023, then grew by 8.39% to $53.2 million in 2024.